Treatment with interferon (IFN) and interleukin (IL)-2 remains the main immunotherapy method for RCC, with the exception of surgery, but only ~10% of advanced RCC patients respond to cytokine-based immunotherapy (1,2). Here, IFNA1 is linked to renal cell carcinoma.